New PRP drug for the Treatment and Prevention of Metastatic Cancer

Chemotherapy and other key cancer treatments have so far only been effective in the elimination of cancer cells that are at the initial stages. Propanc Health Group Corp is a Company developing a revolutionary new drug, which in its trial stages, set to provide a lasting treatment option for advanced cancer cells. It will also prevent the re-growth of cancer cells through metastasis.
By focusing on metastasis as the main and most difficult challenge to treating cancer, Propanc's PRP is designed to ensure that malignant cancer cells cannot transfer to secondary locations and seed new tumors. Its multi-functional cancer fighting properties ensure enhanced production of the naturally occurring protein E-Cadherin to prevent metastasis, prevent the transformation of epithelial cells into mesenchymal cells through epithelial-to-mesenchymal transition (EMT), and prevents cancer cell re-growth, hence preventing the spreading of cancer to vital organs of the body. By restoring E-Cadherin levels, transition of epithelial cells to mesenchymal cells is inhibited in a process that prevents the growth of invasive cells traveling to other parts of the body through the lymphatic system or blood into surrounding tissues. PRP works by altering several critical pathways for cancer cells that otherwise lead to the growth of malignant tumors.
Since the technology behind PRP uses the body's own natural proteolytic enzymes, there is significantly less risk of severe, or even serious side effects on the body compared to current treatments. PRP's targeted approach to killing cancer cells and preventing metastasis may be complementary, or in some cases a preferred option to chemotherapy, which in addition to killing cancer cells, also damages healthy cells in the body. With targeted cancer cell treatment, Propanc's PRP proteolytic proenzymes can potentially be used for long-term treatment.
At pre-clinical stage, Propanc will initially target colorectal and pancreatic cancer tumors in a two-step process of resolving identified tumors and preventing their spread through metastasis. By seeking to test, approve, and patent PRP, Propanc aims to provide its target market with a safe and highly effective treatment that could address later stage cancers.